Research programme: galectin-3 inhibitors - G3 Pharmaceuticals

Drug Profile

Research programme: galectin-3 inhibitors - G3 Pharmaceuticals

Latest Information Update: 21 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator G3 Pharmaceuticals; University Medical Center Groningen; University of Michigan Medical School
  • Class Cardiovascular therapies; Polysaccharides
  • Mechanism of Action Galectin 3 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cardiovascular disorders; Kidney disorders

Most Recent Events

  • 14 Sep 2017 Lead optimisation is ongoing in Kidney disorders and Cardiovascular disorders (PO) (9222922; 3271522)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top